The Valley Desk

NCT03914742 · Interventional trial

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Overall registry status Completed

Phase 1 · Phase 2

Conditions IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov